Jeremy Grantham Intra Cellular Therapies, Inc. Transaction History
Grantham, Mayo, Van Otterloo & Co. LLC
- $30.8 Billion
- Q1 2025
A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 173,001 shares of ITCI stock, worth $22.8 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
173,001Holding current value
$22.8 Million% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
449Shares Held
93.4MCall Options Held
2.24MPut Options Held
1.86M-
Vanguard Group Inc Valley Forge, PA9.52MShares$1.26 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$834 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL5.19MShares$684 Million5.83% of portfolio
-
Davidson Kempner Capital Management LP New York, NY3.49MShares$460 Million16.46% of portfolio
-
Ubs Oconnor LLC Chicago, IL3.09MShares$408 Million28.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...